Australia markets closed

Mesoblast Limited (MSB.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
1.1250+0.0500 (+4.65%)
At close: 04:10PM AEST
Full screen
Previous close1.0750
Open1.0800
Bid1.1100 x 1092600
Ask1.1250 x 5097500
Day's range1.0650 - 1.1250
52-week range0.2550 - 1.3511
Volume5,444,826
Avg. volume12,525,004
Market cap1.284B
Beta (5Y monthly)2.42
PE ratio (TTM)N/A
EPS (TTM)-0.1400
Earnings date29 July 2024 - 02 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1.60
  • GlobeNewswire

    Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

    FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexlemestrocel-L in End-Stage Heart FailureNEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2024. Mesoblast Chief Executive Silviu Itescu said: “We are very pleased with the positive interactions we had last quarter with the FDA, having rec

  • Simply Wall St.

    Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%

    As the Australian market navigates through fluctuating bond yields and anticipates potential interest rate hikes, investors are closely monitoring various economic indicators and corporate activities. Amid these conditions, companies with high insider ownership can be particularly intriguing, as such ownership might align management's interests more closely with those of shareholders, potentially fostering greater resilience and long-term strategic focus during uncertain times.

  • Zacks

    Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

    Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.